Vetr upgraded shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a strong sell rating to a sell rating in a report released on Friday. The firm currently has $13.68 target price on the specialty pharmaceutical company’s stock.

A number of other research analysts have also issued reports on the company. Royal Bank Of Canada set a $19.00 price target on Valeant Pharmaceuticals International and gave the stock a sector perform rating in a research report on Monday, June 19th. Zacks Investment Research lowered Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a research report on Thursday, July 13th. ValuEngine downgraded Valeant Pharmaceuticals International from a buy rating to a hold rating in a research note on Friday, September 1st. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a research note on Sunday, July 30th. Finally, Cantor Fitzgerald reissued a buy rating and issued a $23.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Tuesday, August 29th. Five investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $17.73.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 14.46 on Friday. The firm has a 50-day moving average price of $14.01 and a 200 day moving average price of $13.42. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $24.30. The stock’s market cap is $5.04 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same quarter in the previous year, the firm posted ($0.88) EPS. The firm’s quarterly revenue was down 7.7% on a year-over-year basis. Equities analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/09/valeant-pharmaceuticals-international-inc-vrx-lifted-to-sell-at-vetr-inc.html.

In other news, Director Schutter Richard U. De bought 10,000 shares of the stock in a transaction on Monday, August 21st. The shares were purchased at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.87% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Paulson & CO. Inc. grew its stake in Valeant Pharmaceuticals International by 12.5% in the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Cetera Investment Advisers purchased a new position in Valeant Pharmaceuticals International in the second quarter valued at about $192,000. Scotia Capital Inc. grew its stake in Valeant Pharmaceuticals International by 12.8% in the second quarter. Scotia Capital Inc. now owns 43,235 shares of the specialty pharmaceutical company’s stock valued at $747,000 after purchasing an additional 4,916 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in Valeant Pharmaceuticals International by 85.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 76,792 shares of the specialty pharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 35,378 shares in the last quarter. Finally, Chou Associates Management Inc. grew its stake in Valeant Pharmaceuticals International by 29.7% in the second quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after purchasing an additional 700,000 shares in the last quarter. Hedge funds and other institutional investors own 50.48% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.